Free Trial
NASDAQ:NERV

Minerva Neurosciences Q2 2024 Earnings Report

Minerva Neurosciences logo
$1.48 -0.06 (-3.90%)
As of 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Minerva Neurosciences EPS Results

Actual EPS
-$1.09
Consensus EPS
-$0.97
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

Minerva Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Minerva Neurosciences Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Minerva Neurosciences' Q1 2025 earnings is scheduled for Tuesday, August 5, 2025

Earnings Documents

Minerva Neurosciences Earnings Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
Minerva Neurosciences Inc.
Minerva Neurosciences regains Nasdaq compliance
See More Minerva Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email.

About Minerva Neurosciences

Minerva Neurosciences (NASDAQ:NERV), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

View Minerva Neurosciences Profile

More Earnings Resources from MarketBeat